Atlas Trials

HER2 Exon 20 Mutations

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch HER2 Exon 20 Mutations

RecordFirmDate
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073)ArriVent BioPharma, Inc.2022-06-30

Track HER2 Exon 20 Mutations automatically

Every clearance here is in the API, with alerts when new ones post.